The failure of many promising treatments for Alzheimer’s is driving many pharmaceutical companies out of the field, reports the National Post.
According to UBC Alzheimer’s expert Howard Feldman, there are very few treatments in the pipeline, partly because of an assumption–since disproved–that reducing amyloid plaque in the brain would help patients get better. The disease proved much more complex than this model suggested, Feldman said.
